Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss

Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss

Source: 
Endpoints
snippet: 

As the obesity epidemic in America worsened throughout the years, many biotechs cropped up hoping to develop weight-loss drugs that would help stem this tide. But now, Novo Nordisk’s diabetes cash cow semaglutide is showing such startlingly effective results in obesity that it may have a head start in cornering the market.